These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 29933822)
21. [Pharmacological and psychosocial interventions for cannabis use disorders]. Budney AJ; Vandrey RG; Stanger C Braz J Psychiatry; 2010 May; 32 Suppl 1(0 1):S46-55. PubMed ID: 20512270 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Cengel HY; Bozkurt M; Evren C; Umut G; Keskinkilic C; Agachanli R Psychiatry Res; 2018 Apr; 262():46-54. PubMed ID: 29407568 [TBL] [Abstract][Full Text] [Related]
23. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917 [TBL] [Abstract][Full Text] [Related]
24. Cannabis use disorder: epidemiology and management. Copeland J; Swift W Int Rev Psychiatry; 2009 Apr; 21(2):96-103. PubMed ID: 19367503 [TBL] [Abstract][Full Text] [Related]
25. Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Sherman BJ; McRae-Clark AL; Baker NL; Sonne SC; Killeen TK; Cloud K; Gray KM Am J Addict; 2017 Mar; 26(2):136-144. PubMed ID: 28152236 [TBL] [Abstract][Full Text] [Related]
26. Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015. Maloney-Hall B; Wallingford SC; Konefal S; Young MM Health Promot Chronic Dis Prev Can; 2020 Jun; 40(5-6):176-183. PubMed ID: 32529977 [TBL] [Abstract][Full Text] [Related]
27. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Brezing CA; Levin FR Neuropsychopharmacology; 2018 Jan; 43(1):173-194. PubMed ID: 28875989 [TBL] [Abstract][Full Text] [Related]
35. Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. Panlilio LV; Justinova Z Neuropsychopharmacology; 2018 Jan; 43(1):116-141. PubMed ID: 28845848 [TBL] [Abstract][Full Text] [Related]
36. Cannabis Withdrawal - A New Diagnostic Category in DSM-5. Katz G; Lobel T; Tetelbaum A; Raskin S Isr J Psychiatry Relat Sci; 2014; 51(4):270-5. PubMed ID: 25841223 [TBL] [Abstract][Full Text] [Related]
37. Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series. Trigo JM; Soliman A; Staios G; Quilty L; Fischer B; George TP; Rehm J; Selby P; Barnes AJ; Huestis MA; Le Foll B J Addict Med; 2016; 10(4):274-9. PubMed ID: 27261670 [TBL] [Abstract][Full Text] [Related]
38. Exercise as an adjunctive treatment for cannabis use disorder. Brellenthin AG; Koltyn KF Am J Drug Alcohol Abuse; 2016 Sep; 42(5):481-489. PubMed ID: 27314543 [TBL] [Abstract][Full Text] [Related]
39. Treatment of adolescents with a cannabis use disorder: main findings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands. Hendriks V; van der Schee E; Blanken P Drug Alcohol Depend; 2011 Dec; 119(1-2):64-71. PubMed ID: 21684088 [TBL] [Abstract][Full Text] [Related]